Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05056402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revised
    • Secondary endpoints revised (6)
    v5
  2. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2025
    • Secondary endpoints: 5 to 6
    v4
  3. Primary completion date: Dec 31, 2022 to Dec 31, 2023v3
  4. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 1300 to confirmed 1382
    • Site contact updated
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in healthy population aged 9-17 years old in comparison with aged 18-26.
Trial Details
NCT Number NCT05056402
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Conditions
(from sponsor)		 Cervical Cancer, Condylomata Acuminata
Related terms Condylomata Acuminata, Uterine Cervical Neoplasms
Enrollment 1,382 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov